Friday, 29 March 2024


Coherus starts ph3 trial of rheumatoid arthritis biosimilar drug

24 April 2014 | News | By BioSpectrum Bureau

‎Singapore: US based biosimilar therapeutic developer, Coherus BioSciences, has started its Phase 3 trial of CHS-0214, an investigational etanercept biosimilar for rheumatoid arthritis (RA).

The Phase 3 trial is a randomized, double-blind, active-control, parallel-group, multicenter, global study in subjects with active RA who have demonstrated an inadequate response to methotrexate..

"The initiation of a CHS-0214 Phase 3 study is an important event for RA patients," said Dr Barbara Finck, chief medical officer, Coherus. "This trial of biosimilar etanercept advances our goal to expand access to this life-changing medication for patients with RA."

"This trial marks our transition to a Phase 3 company," said Mr Denny Lanfear, chief executive officer, Coherus. "In concert with our partners, Daiichi Sankyo and Baxter, we are pleased to advance this product to the final stage of development."

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account